A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
Phase of Trial: Phase I/II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Atezolizumab (Primary) ; CDX 1401 (Primary) ; Guadecitabine (Primary) ; Poly ICLC
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Sep 2017 Planned End Date changed from 31 Dec 2018 to 31 Mar 2020.
- 29 Sep 2017 Planned primary completion date changed from 31 Dec 2018 to 31 Mar 2020.
- 29 Sep 2017 Status changed from not yet recruiting to recruiting.